- LOGIN
- MemberShip
- 2026-05-12 17:14:55
- Policy
- MFDS nizatidine investigation expands to drug products
- by Lee, Tak-Sun Nov 07, 2019 08:54am
- Signs of Ministry of Food and Drug Safety (MFDS) expanding investigation on nizatidine medicine have been spotted. Sources have reported the ministry is now collecting complete drug product samples for further investigation after collecting active pharmaceutical ingredient (API). Pharmaceutical industry is concerned over the ministry’s deepening investigation as it could mean the regulator’s administrative action is imminent. According the industry on Nov. 5, MFDS collected nizatidine products stocked at pharmaceutical companies on Nov. 4. After collecting API samples last week, the ministry is pushing boundary of investigation to confirm possible carcinogen contamination of complete product. API samples, manufactured from five years ago to date, were taken, and now drug products manufactured since 2018 were also sent to MFDS. The industry says API impurity analysis would take about two to three days, and product analysis would take about three to four days. Accordingly, MFDS would take some time to decide on next move based on the test result. But the industry believes MFDS has probably already found NDMA in a sample of nizatidine API at an exceeding level. “Standard level of NDMA in nizatidine is 0.32ppm. Highly likely that MFDS decided to collect more samples because it found a sample surpassing the standard level. As the ministry even collected API manufactured five years ago, it could be contemplating on the possibility of contamination in storage,” an industry associate commented. Apparently, many of manufacturing plants have already suspended production of nizatidine, while companies stopped marketing for the drug as well. Some reported a company dropped its drug approval application. In such turmoil, the industry predicts MFDS to take an action on nizatidine medicine next week at latest.
- Policy
- “MOHW neglected 10000 practices by 56 suspended doctors”
- by Kim, Jung-Ju Nov 04, 2019 03:11pm
- Sources report tens of doctors, Korean medicine doctors and dentists with suspended licenses have practiced over 11,000 medical services and claimed over 800 million won of insurance reimbursement. The Board of Audit and Inspection of Korea (BAI) notified the details the health authority and ordered to take a corrective action on its negligence on obligated monitoring of suspended healthcare providers. On Oct. 31, BAI officially disclosed a Ministry of Health and Welfare (MOHW) management audit report on containing the details. The audit was conducted on the ministry’s inappropriate internal and external practices. The audit report on the ministry’s management negligence over healthcare providers with license suspended from illegal practice found 56 doctors, dentists and Korean medicine doctors have practiced 11,102 cases of medical service. Moreover, the doctors received 808,358,420 won of National Health Insurance (NHI) reimbursement claimed from HIRA, during their suspended license period. Field inspection on two doctors and a Korean medicine doctor randomly selected by MOHW from the 56 suspended doctors, confirmed their medical practices. The Korean medicine doctor, for example, practiced total 1,469 cases of medical service from last Jan. 1 to Mar. 6, such as acupuncture on outpatient with spinal pain. The doctor claimed and received 38,510,110 won of NHI reimbursement. BAI estimates two other doctors have practiced medical service on outpatient and inpatient during their suspension period and received back 176,649,200 won and 3,816,360 won, respectively, for NHI reimbursement. And BAI pointed out MOHW was completely unaware of the situation and did not revoke their licenses. Regarding the issue, MOHW accepted BAI’s audit result and suggested it would establish a system to inspect medical service practiced by suspended healthcare providers by cooperating with related government agencies, and also impose appropriate penalty to 56 doctors, who have been paid with NHI reimbursement, after a thorough inspection on any medical service practiced during their suspension period. BAI ordered Minister of Health and Welfare to take appropriate action on the 56 healthcare providers, such as field inspection, and establish a system to monitor and inspect healthcare providers’ practice during their license suspension period.
- Policy
- First year of Rare Disease Support Scheme
- by Eo, Yun-Ho Nov 04, 2019 08:13am
- The biggest issue of the policy is ‘lack of interest’. ‘Rare disease’ is not a specific categorization, but rather it is designated based on frequency of diagnosis. Korea defines ‘rare disease’ as a disease diagnosed to less than 20,000 people. With small patient size and lack of drug, these diseases are in dire need of new drug. But the voices of small handful of patients are easily lost in the air. At the moment in Korea, 951 diseases are designated as subject for Rare Disease Medical Aid Program, in which 927 of them are eligible for special case benefit. The total of 927 consists of 827 rare diseases as defined by the National Health Insurance special case copayment benefit system, and about 100 more added, as of August 2017, by a rare disease survey reflecting opinions of patients and their families, patient advocacy group, and medical experts. Previously, the government did not have a government-managed rare disease list without sufficient legal basis to back it up. So the size of rare disease patients was estimated according to the special case benefit subject list. Rare and chronic diseases were confused and defined as one keeping rare disease related policy making and researches limited. But growing voices criticized government for neglecting rare disease, and finally the Rare Disease Management Act was enacted in 2016. Since then, the first Rare Disease Management Plan was established, and in September 2018, the Rare Disease Patient Support Scheme was first implemented as more demanded for state-level rare disease patient support like disease management, treatment and prevention. ◆Rare disease patients supported by government:The objective of the Rare Disease Patient Support Scheme was to lessen patient’s financial burden of medical expense. The health authority applied special case benefit on the new rare diseases and expanded eligible disease for low-income patient medical aid. Including the newly designated 100 rare disease, now about 1,800 patients receive special case benefit, annually. Special case benefit system for rare disease patient started from applying 20 percent of copayment rate on artificial kidney dialysis or continuous ambulatory peritoneal dialysis for chronic kidney failure patients, and the benefit continued to expand on hemophilia, Gaucher’s disease, leukemia and cancer patients. But some undiagnosed rare disease patients had been excluded from the special case benefit due to unidentifiable diagnosis and disease code with limited patient size. And from last January, the roster for special case benefit and rare disease medical aid program subject diseases were unified. The revised regulation also stipulated special case benefit for undiagnosed rare disease patients without a disease code. Medical aid subject disease roster expanded significantly from 652 to 927 cases, granting financial support to about 2,600 more patients. Compared to last year, the Rare Disease Medical Aid Program bumped up this year’s budget and allocated about 32 billion won. The Rare Disease Patient Support Scheme includes Rare Disease Diagnosis Support Program to prevent patients from missing adequate treatment timing with difficulty in diagnosis. The diagnosis support program covers patients with Genetic Testing Support subject disease and undiagnosed condition. Also from this year, Rare Disease Regional Care Center Network has been expanded to ten centers, consisting of one Central Support Center and other Regional Support Centers. To sum it up, the Rare Disease Support Scheme mainly focuses on ▲establishing rare disease list and registration system, ▲increasing medical aid to reduce financial burden, and ▲expanding rare disease diagnosis support and Regional Support Centers. ◆Only 5% of diseases have treatment and NHI coverage rate is still low: Despite the government’s effort, some rare disease patients are still struggling to get access to treatment. Only about five percent of rare diseases have treatment developed. Diagnosis and treatment developments are far slower than other general medical conditions, because of small limited number of patients and prospective profit estimated low. And even if better treatments are developed, many of them are unapproved or non-reimbursed, leaving patients hopeless. Without guaranteed National Health Insurance (NHI) coverage on treatment, patients and their families would suffer not only from physical pain, but also with financial strain. More than 80 percent of rare diseases are inherited and patient’s family member show similar conditions. This vicious cycle leads medical expense in one single household to surge exponentially. However, the current Rare Disease Management Act does not specifically stipulate expansion of NHI coverage on rare disease treatments. Related industry claims Korea lacks a legal basis to back policy and regulation to boost pharmaceutical accessibility for rare disease patients catering unique qualities of the disease. Korea may have established a meaningful legislation of Rare Disease Management Act, but in fact, the law does not help many of struggling patients to get better access to drug to this date. Even at the National Assembly Annual Audit session, lawmakers urged the government to enhance NHI coverage on rare disease. Lawmaker Yoon Jong-pil of Liberty Korea Party spoke at Ministry of Health and Welfare audit session and pointed out, “Considering exceptionally limited number of patients and difficulty in developing effective treatment, rare disease treatment should be reviewed with more flexible criteria or they would not be accessible to patients in need”. .Drug pricing department of a multinational pharmaceutical company claimed, “An independent set of reimbursement review criteria should be designed for rare disease treatment as it is impossible to evaluate with common economic sense .And this is why special clause or supplementary article as a part of Rare Disease Management Act should stipulate expansion of coverage on rare disease treatment” .
- Policy
- Industry burdened but accepting of mandatory DSUR
- by Byun Kyung A Oct 31, 2019 09:59am
- Pharmaceutical industry initially complained of administrative strain when the government issued a notice on enforcing mandatory drug safety update report (DSUR)’, as advised by the National Assembly. But the industry also agrees with Korean government’s intention to enforce the pre-marketing regulation, which now has become a global trend. The pharmaceutical industry sees why the government would rather tighten the pre-marketing regulation than to cause actual corporate loss and public confusion over post-marketing recall and reimbursement and approval revocation. According to the lawmakers and pharmaceutical industry on October 27, Ministry of Food and Drug Safety (MFDS) plans to enforce mandatory submission of DSUR to strengthen clinical trial safety control. Currently, the Pharmaceutical Affairs Act does not stipulate mandatory DSUR submission. Along with post-marketing periodic safety update report (PSUR), DSUR has been an issue as a whistleblower from MFDS reported how “the ministry neglects its most basic job and does not even review submitted drug safety materials”. Criticism on MFDS neglecting drug review expertise grew intensely as drug quality and safety issues, such as ranitidine impurity incident and Invossa-K approval revocation, surfaced all at once. Accordingly, the lawmakers tackled the ministry on DSUR and PSUR management at the recent National Assembly Annual Audit. MFDS accepted the criticism and vowed to reinforce related regulation. MFDS official stated, “The ministry reviewed a total of 2,823 PSUR materials in last five years, and drug safety information reported from around the world were evaluated and reflected during the reexamination period”, and “mandatory DSUR would be enforced from 2020 based on the five-year National Health Insurance Comprehensive Plan announced last August”. Starting with new drug, MFDS is to phase in mandatory DSUR submission from next year considering pharmaceutical industry’s human resource, cost and other preparation procedure. Pharmaceutical industry showed mixed feelings of burden and need of the tightened regulation. Many also saw DSUR as unavoidable task the industry should take in as it is a pre-marketing regulation in clinical trial phase. “It is difficult to happily accept the new regulation as a company. DSUR submission, despite the phase-in introduction, would inevitably burden the industry with development cost and time,” but “we do agree the regulation is needed. Already many pharmaceutically advanced countries have enforced mandatory DSUR and it is now a global trend Korea cannot avoid,” a pharmaceutical administrative personnel from Korean pharmaceutical company commented. The Korean company associate also added, “Time would not be much of an issue, as it would be applied to new drug first, and give plenty of preparation time. The regulation aims to reinforce drug safety measures before commercialization, and not to be an excessive over-regulation. MFDS officials would probably convene a regulatory seminar for companies”. A multinational pharmaceutical company insider predicted DSUR would be less of a problem, as it regulates pre-marketing phase and not post-marketing. The multinational company associate said, “The authority has been trying to swiftly solve recent drug safety and approval revocation issues with strict regulation, retrospectively. Meanwhile, DSUR is a pre-marketing regulation that minimizes post-marketing measures but raises the bar for drug safety management. The actual strain on the industry would be relatively insignificant”.
- Policy
- Weighted pricing benefit abused as permanent price booster
- by Byun Kyung A Oct 31, 2019 09:58am
- The government evaluated the current weighted drug pricing system has been digressed as a permanent pricing benefit. Apparently, 96 percent of items have maintained the benefitted pricing for more than three years, and the authority sees that such practice has distanced itself from the initial objective to secure stable supply. Ministry of Health and Welfare (MOHW) submitted a statement answering the National Assembly Health and Welfare Committee Audit addressing the issue. Previously, Liberty Korea Party Lawmaker Kim Soon-Rye questioned the ministry about revising drug pricing system and strengthening competitiveness of Korean companies. In summer, MOHW presented revised 'Decision-making and Modification Standard for Drug Item' and unveiled weighted pricing system revision plan as a part of generic pricing system revision. The system was revised to set one year period of weighted pricing for synthetics and biopharmaceuticals, but provides maximum two years in case number of companies supplying the equivalent generics is less than three. The revision also established generic drug pricing standard and pricing for multi and single-use eye drops. On the revised weighted pricing system, MOHW explained “The initial objective of the system was to stabilize drug supply (weighted pricing for generics with less than three suppliers) and to induce soft landing for a generic entering the market where the original is lowering its price, from 100 percent to 70, and then to 50 percent.” “The revision was planned to keep the regulation faithful to its original objective maintaining stable drug distribution”, the ministry added. And the government emphasized its justification of drug pricing system revision as “244 out of 254 items, or 95 percent of the benefited items have been maintaining its increased price for more than three years, abusing the system as a permanent price boosting tool”. The ministry also ensured it would thoroughly review individual cases that need special support to stabilize drug supply. The statement added MOHW’s commitment to contribute strengthening Korean pharmaceutical company’s global competitiveness by executing the Biohealth Industry Innovation Strategy and Pharmaceutical Industry Fostering and Support Master Plan.
- Policy
- For reimbursed drug, efficacy and cost-efficiency come first
- by Byun Kyung A Oct 31, 2019 09:34am
- On the last day of the 20th National Assembly Annual Audit for the Health Insurance Review and Assessment Service (HIRA), half the questions were dedicated to pharmaceutical affairs. The lawmakers of the NA Health and Welfare Committee questioned HIRA about NHI reimbursement reevaluation on dementia treatment choline alfoscerate, reimbursement expansion on NOAC Xarelto, and reimbursement expansion on the anticancer treatment reflecting its frequent non-reimbursed off-label use as ophthalmic solution. Some lawmakers claimed the General Principle of Healthcare Reimbursement on liquid solutions, like syrup and suspensions, should be revised and expand utilization cap eligible for reimbursement. As always, however, HIRA had a strictly basic answer for the said topics and stated, “The issues addressed would be sufficiently reviewed when clinical efficacy and cost-efficiency are proven”. Below is Daily Pharm’s summary of HIRA’s written answer submitted to the NA on Oct. 28. ◆Reimbursement reevaluation on choline alfoscerate: The current system does not stipulate a reevaluation for NHI reimbursement based on clinical efficacy, except for special cases of Ministry of Food and Drug Safety (MFDS) revoking an approval. The government's National Health Insurance Comprehensive Plan is to establish a pharmaceutical reevaluation system considering clinical efficacy of listed drug, financial impact and healthcare coverage listing status in foreign countries. HIRA, then, plans to have Drug Post-evaluation Subcommittee under Drug Reimbursement Evaluation Committee (DREC) to conduct NHI reimbursement feasibility reevaluation with the new system. Particularly, HIRA official stressed uncertainty of choline alfoscerate “has been questioned constantly” and that the agency would “establish reevaluation system promptly for it”. The dementia treatment is usually sold as a health functional food in other countries. ◆Expanded reimbursement benefit on Xarelto: Medical industry urges the health authority to grant NHI benefit on new oral anticoagulant (NOAC) Xarelto (rivaroxaban) to high-risk patients with coronary artery disease (CAD), specifically for cases of atrial fibrillation (AF) before and after catheter ablation and electrical cardiodiversion, nonvalvular AF with hypertrophic cardiomyopathy, and nonvalvular AF with CHA₂DS₂-VASc score 1. At the moment, Brilinta (ticagrelor) and Xarelto are listed for reimbursement as antiplatelets, and the benefit for Xarelto only covers high-risk patients with nonvalvular AF. HIRA answered, “As medical academic society has requested expanding reimbursement benefit on Xarelto, the agency plans to promptly review additional clinical evidences, such as revised guideline in foreign countries”, and the treatment’s “reimbursement would be expanded depending on clinically proven efficacy”. ◆Revising General Principle for syrup and suspensions: The current General Principle on Healthcare Reimbursement Criteria and Method stipulates granting NHI reimbursement benefit on pharmaceutical syrup and suspensions, also available in types of table or capsule with equivalent ingredient, in following cases; prescribed to patients younger than 13; patients with old age, dementia or other dysfunctional esophagus unable to swallow; prescribed with antacid, sucralfate, and sodium alginate under approved indication. The National Assembly pointed out the General Principle regarding pharmaceutical liquid solution should be amended and provide healthcare benefit for all Koreans to consume drug more conveniently. But HIRA official explained, “Liquid solution tends to be more expensive than tablet or capsule drugs”, therefore, “the General Principle, on Oct. 1, 2011, stipulated providing benefit to subject drugs meeting cost-efficiency standard under certain medical state and patient condition”. Since 2011, some syrup and suspension with proven cost-efficiency have received reimbursement as an exception to the General Principle. HIRA official added, “The agency would accordingly review the need to amend general reimbursement criteria based on cost-efficiency standard”. ◆Listing Avastin for reimbursement: This year’s National Assembly Audit addressed promptly providing reimbursement for non-reimbursed off-label treatment approved to be used. The issue refers to the use of anticancer treatment Avastin in ophthalmology as a non-reimbursed off-label treatment for macular generation. After consulting with Ministry of Food and Drug Safety (MFDS), HIRA allowed request for use of non-reimbursed treatment at clinics without an institutional review board (IRB) by revising ‘Standard and Procedure of Requesting Usage Approval of Non-reimbursed Off-label Drug’ this month. HIRA stated it would consider providing healthcare reimbursement benefit in the future, when the legitimately used off-label drugs meet clinical efficacy and cost-efficiency standards. ◆Expanding RSA for follow-on drugs: As the RSA subject regulation for severe disease has been revised in last July, HIRA plans to positively review feasibility of expanding RSA subject for follow-on drugs after collecting public opinions. ◆Preventing illegal drug distribution: HIRA has decided to upgrade monitoring system to better manage all drug distribution information and to utilize the collected information properly through the serialization system. HIRA currently requires a serial number to be labeled on minimal drug distribution unit container for the health authority to track individual unit in all phase of distribution, from manufacturing to import, distribution, and consumption. In last May, HIRA cooperated with Seoul city community police to investigate illegal distribution of a weight-loss medicine Saxenda injection. ◆Drug pricing standard for the revised Generic Pricing Policy: The latest revision in the Generic Drug Pricing Policy stipulates drug pricing differentiated with compensation for cost, time and investment spent on generic development, and revised weighted pricing system. Nonetheless, the pricing standard for incrementally modified new drug is same as before. As the new weighted pricing policy could bring down prices of some incrementally modified drugs (IMD), HIRA plans to adequately amend the standard with Ministry of Health and Welfare. HIRA official said, “IMDs are mostly developed by Korean pharmaceutical companies, so drug pricing benefit without limitation on IMD could cause international trade discrepancy as unfairly favorable benefit for Korean companies only”, but “the agency would continue to talk to other related ministries and industry about other means to promote development of IMD with better clinical efficacy”. ◆Revising PE analysis review process: In Australia and Canada, a company is responsible for submitting pharmaco-economic analysis and a public agency is responsible for reviewing the submitted material. But in Korea, pharmaceutical companies have difficulties editing submitted PE analysis report. Lawmakers claimed Korea should adopt ‘Application Registration System’ to prevent such inconvenience. HIRA official answered, “it would be reviewed in detail, surveying overseas cases and current conditions in Korea”.
- Policy
- Jext, only distributed to KOEDC for profits
- by Lee, Jeong-Hwan
- The company that exclusively deals with one of urgent drugs, Jext used for allergic reaction Shock (Anaphylaxis) was criticized for distributing drugs only through KOEDC( Korea orphan & Essential Drug Centers ) for profit. Even though Jext was listed insurance registration last July and it is possible for the company to make direct distribution, The price between general reimbursement and KOEDC reimbursement has big difference. So, Jext distributed only to KOEDC. According to the patients and KOEDC on the 11th, Jext has been distributed and sold patients only through KOEDC since domestic reimbursement listed. It is in patients and KOEDC view that KOEDC reimbursement is much higher than general reimbursement, and it makes economic burden to patients. The company says it is not for profit at all. The headquarters regulates the distribution of general reimbursement items, so the company is inevitably unable to distribute the supply. In fact, KOEDC reimbursement price of Jext is ₩134,933 more than double the general reimbursement price is ₩56,670. The company distributes Jext only through KOEDC until insurance registration listed. But it is still on sale only through KOEDC, even though Jext got general reimbursement listed and can be distributed at clinics or retail pharmacies. The reimbursement price of KOEDC is calculated based on the import cost, whereas the general reimbursement price is meticulously formulated through registraion procedure of Health Insurance Review & Assessment Services. It is the majority opinion of reimbursement specialists that it is much more profitable to sell at KOEDC than to distribute Jext at the general imbursement. Furthermore, the distribution of Jext through KOEDC significantly reduces additional marketing and management tasks such as account management costs required for direct distribution. That's one of the reasons why the direct distribution is delayed. However, if the distributor don't handle the medicine reimbursement listed directly for 6 months, the regulatory action is removed. It even raises doubts that the company deliberately distributes Jext only to KOEDC. Regardless of the company's intentions, as a result, patients need to get Jext ony by paying more expensive money through KOEDC because thiere is no distribution volume, even though there is a way to purchase Jext at significantly lower reimbursement. KOEDC official said, the prodcut is not in shortage of distribution, but the the company distributes medicines only to KOEDC and dose not supply them directly. It's reluctant. In the end, patients have to go and buy through KOEDC with higher price for almost 6 months even after reimbursement listed, there has never been a company using this trick so far. The deliberate coordination disregards the purpose of establishing KOEDC and the policy of expanding access to ER medicines for patients. In response to such criticism, the company said that it is not a distribution control for profitability, and will start direct distribution as soon as possible. The company official said, It was true that Jext was distributed only to KOEDC after July when reimbursement listed, but it was not intended. It was a supply disruption at the headquarters in preparation for improved Korean insert, etc. The official added, "The company will import Jext products within this month and supply them directly from next January after our own quality inspection".
- Policy
- "최저 생존율 난소암, '린파자·엘라히어' 신속 급여가 해법"(K)
- by Lee, Jeong-Hwan
- [데일리팜=이정환 기자]아스트라제네카 린파자(성분명 올라파립)와 애브비 엘라히어(성분명 미르베툭시맙 소라브탄신)의 건강보험급여 신속 적용으로 우리나라 난소암 환자들의 낮은 생존율을 하루빨리 개선해야 한다는 제언이 나왔다.특히 난소암 치료제 건보급여 확대는 정부의 제2차 국민건강보험 종합계획 2026년도 시행계획안에 명시된 내용으로, 급여 접근성 확대 타당성이 크다는 지적도 뒤따랐다.12일 삼성서울병원 이유영 교수는 이주영 개혁신당 의원이 개최한 난소암 환자 치료 접근성 강화 정책 토론회에서 '난소암 생존율 향상을 위한 치료 접근성 강화·건강보험 보장성 개선과제'를 통해 이같은 견해를 밝혔다.이유영 교수는 난소암 유발률이 낮지만, 발병이 확인되면 사망률이 높은 가장 치명적인 여성암이라고 소개했다. 실제 국내 난소암 환자 발생률은 인구 10만명당 약 12명 수준이자 전체 여성암의 2.4%, 전체 암 발생의 1.2%다.그러나 환자 수는 1999년 1353명에서 2022년 3263명으로 약 2.4배 늘어 20년 동안 꾸준히 증가세다. 최근 5년 가파른 상승세를 기록중인데 고령화와 출산율 변화 등이 영향을 미쳤다.특히 난소암의 5년 생종률은 66.7% 수준으로 주요 여성암 가운데 최저를 기록중이다. 한 해 1465명이 사망해 여성암 사망 8위에 랭크됐다.이에 환자 생존율 향상을 위해서는 조기 진단과 함께 적극적인 유지 요법이 필요하다는 게 이 교수 설명이다.난소암 생존율이 크게 낮은 이유는 약 70% 수준에서 암이 복강 내 광범위하게 퍼진 상태인 3·4기 때 진단·발견되는 게 대부분이기 때문이다.초기 증상이 모호하고 효과적인 조기 검진법이 없는데다 복강 깊숙히 위치해 암 발병 이후 빠르게 전이되는 질환 특수성도 낮은 생존율에 영향을 미쳤다.이 교수는 임상시험(SOLO1, PRIME, PRIMA, PAOLA-1) 연구 결과를 근거로 유전자 검사에서 HRD(상동재조합 복구 결핍) 양성이 확인된 난소암 환자에게 PARP 억제제를 투약하면 재발 위험을 40~70% 낮추고 사망 위험은 30~40% 감소시킬 수 있다고 피력했다.HRD 환자에 한해 베바시주맙과 린파자 병용으로 생존율을 크게 향상할 수 있다는 게 이 교수 취지다.아울러 이 교수는 재발이 심한 백금 저항성 난소암(PROC) 환자에게는 기존 항암요법인 베바시주맙 이후 약 10년만에 전체생존기간과 무진행 생존기간 개선을 입증한 항체-약물접합체(ADC) 급여를 통한 치료 접근성 확대를 제언했다.이 교수는 "PARP 억제 기전 치료제인 올라파립과 베바시주맙 병용요법은 HRD 양성 환자에서 무진행생존율을 30개월 가까이 연장해 암이 진행되거나 사망할 위험을 59% 감소시켰다"며 "올라파립+베바시주맙 병용은 HRD 양성 난소암에서 유일하게 전체생존율을 개선했다"고 강조했다.그러면서 "HRD 환자에 올라파립+베바시주맙 병용은 NCCN(미국종합암네트워크) 가이드라인에서도 유일한 카테고리1으로 권고중이며 주요 선진국 역시 표준 요법으로 인정하고 있다"며 "그러나 국내 현실은 전제생존율을 입증한 치료제가 여전히 비급여인 상황으로 환자 치료 접근성이 제한되고 있다"고 말했다.이 교수는 "백금 저항성 난소암의 경우 베바시주맙 이후 오랜만에 엘라히어주가 무진행 생존기간 개선을 유의미하게 입증했다"며 "ADC인 엘라히어주는 세포독성 약물을 종양 세포에 표적 전달하도록 설계된 새로운 계역의 약으로, 생물학적 유도 미사일 역할을 수행한다"고 했다.이 교수는 난소암 치료제 환자 접근성 강화를 위해 선급여-후평가 제도, 비용-효과성 평가 유연화, ICER 임계값 상향·탄력 적용을 비롯해 혁신신약 보험등재 과정 전반에서 임상 전문가 의견을 적극 수용해 실제 치료 현장의 미충족 수요와 임상 필요성을 급여 평가 때 충실히 반영할 필요가 있다고 주장했다.HRD 양성 환자에 대한 베바시주맙+올라파립 병용, 백금 저항성 난소암 환자에 대한 ADC 신약 엘라히어주 급여를 적극적이고 신속하게 적용해야 한다는 취지다.그는 "난소암은 진단 때 상당수가 3기~4기 진행성인데다 재발이 빈번해 부인암 중 생존율이 가장 낮다. 혁신신약의 신속 급여 등재와 급여 확대를 통한 난소암 환자 치료 접근성·보장성 강화가 시급하다"며 "난소암은 정부의 보장성 강과 정책의 핵심 우선 대상인 만큼 급여 접근성의 조속한 확대가 필요하다"고 피력했다.
